PD-1/PD-L1
PD-1/Programmed death-ligand 1
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.
PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.
All Product Categories
-
PD-1/PD-L1 Inhibitors
(349)
View all products
-
PD-1/PD-L1 Agonists
(5)
View all products
-
PD-1/PD-L1 Antagonists
(11)
View all products
-
PD-1/PD-L1 Activators
(16)
View all products
-
PD-1/PD-L1 Modulators
(7)
View all products
-
PD-1/PD-L1 Inducers
(3)
View all products
-
PD-1/PD-L1 Degraders
(13)
View all products
-
PD-1/PD-L1 Control
(1)
View all products
-
PD-1/PD-L1 Substrates
(2)
View all products
-
PD-1/PD-L1 Ligands
(7)
View all products
-
PD-1/PD-L1 Related Products (464)
Related Products (464)
-
Antibodies (8)
-
PD-1/PD-L1-IN-44
0 ImagesCat. No.: HY-161518PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC50=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8+ cell infiltration.
-
PROTAC BRD4 Degrader-33
0 ImagesCat. No.: HY-174811PROTAC BRD4 Degrader-33 is a BRD4 PROTAC degrader that recruits CRBN. PROTAC BRD4 Degrader-33 downregulates PD-L1 expression, inhibits tumor cell proliferation and tumor growth in mice by inducing ubiquitination and proteasomal degradation of BRD4. PROTAC BRD4 Degrader-33 can be used in the research of breast cancer.
-
AM0001
0 ImagesCat. No.: HY-P991347AM0001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. AM0001 can be used in cancer research.
-
Manelimab
0 ImagesCat. No.: HY-P99723CAS No.: 2168561-26-8Synonyms: BCD-135
-
FM213
0 ImagesCat. No.: HY-P11891FM213 is a PD-L1 inhibitor with a human IC50 of 323 nM. FM213 blocks PD-1/PD-L1 protein-protein interactions, and promotes endocytosis and lysosome-dependent degradation of PD-L1 on the surface of cancer cells. FM213 binds to PD-L1 on cancer cells and exosomes, and enhances the recognition and killing of cancer cells by human PBMC. Combination of FM213 with the TIGIT inhibitor DTBP-3 (HY-P11903) enhances anti-tumor immunity. FM213 can be used in research related to non-small cell lung cancer.
-
15N-Labeled Camrelizumab
0 ImagesCat. No.: HY-P9971S15N-Labeled Camrelizumab is the 15N-labeled Camrelizumab (HY-P9971). Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab?binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as?anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
-
CYP51/PD-L1-IN-1
0 ImagesCat. No.: HY-156149CAS No.: 3032386-49-2CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.
-
STT-001
0 ImagesCat. No.: HY-P991357STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research.
-
Lumipodlin
0 ImagesCat. No.: HY-187796CAS No.: 2368183-94-0Lumipodlin is a programmed cell death ligand 1 (PD-L1) inhibitor. Lumipodlin is an antitumor agent that can be used in cancer-related research.
-
PD-L1-IN-5
0 ImagesCat. No.: HY-162357CAS No.: 2597056-85-2PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC50 value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo.
-
LSD1-IN-27
0 ImagesLSD1-IN-27 is an orally active LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer.
-
Cadapersen
0 ImagesCat. No.: HY-177620CAS No.: 2924115-64-8Synonyms: RG6084; RO-7191863Cadapersen (RG6084) is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).
-
1-Caffeoylquinic acid (Standard)
0 Images1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the inhibitor for PD-1/PD-L1.
-
PDL1 degrader-4
0 ImagesCat. No.: HY-184300PDL1 degrader-4 is a PD-L1 degrader that induces PD-L1 degradation via the LAMP2-mediated lysosomal pathway, with a Kd value of 5.58 μM. PDL1 degrader-4 induces anti-tumor immunity through PD-L1 degradation. PDL1 degrader-4 is applicable to research related to non-small cell lung cancer.
-
PD-1/PD-L1-IN-54
0 ImagesCat. No.: HY-159892CAS No.: 1393644-68-2PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (KD: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC50: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8+ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.
-
PD-1/PD-L1-IN-26
0 ImagesCat. No.: HY-144746CAS No.: 2966090-78-6
-
PD-1/PD-L1-IN-49
0 ImagesCat. No.: HY-163844PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC50 of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint.
-
GR-1405
0 ImagesCat. No.: HY-P991354GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research.
-
PD-1/PD-L1-IN-59
0 ImagesCat. No.: HY-179180CAS No.: 2891831-40-4PD-1/PD-L1-IN-59 (Compound MZ51) is a PD-1/PD-L1 inhibitor with an IC50 of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC).
